Newsletter Watch: Small-cap medical stocks

Ticker Tape Digest editor Leo Fasciocco recently chose Natus Medical (Nasdaq:BABY) and Kensey Nash (Nasdaq:KNSY) as his favorite small-cap picks.

Newsletter Watch: Royce Global Value

Given the market's high volatility, it may be an ideal time for investors to consider the Royce Global Value Fund (MUTF:RIVFX) — a small-cap fund with a focus on global opportunities within the framework of value-oriented investing.

Newsletter Watch: China BAK Battery

Read why Asia Stock Alert editor Tony Sagami recently chose China BAK Battery (Nasdaq:CBAK) as his latest recommendation.

Newsletter Watch: Elixir Gambling Technologies

With a micro-cap valuation of just $188 million and a “penny stock” price, Elixir Gaming Technologies (AMEX:EGT) is a high-risk company.

Newsletter Watch: Beijing bets

This week, we have a pair of intriguing plays on the rise in demand by Chinese consumers for higher quality — and healthier — foods: China Agritech (Nasdaq:CAGC) and American Oriental Bioengineering (Nasdaq:AOB).

Newsletter Watch: Favorite small-cap funds

This week, we follow up on our previous two Newsletter Watch columns, returning to favorite ideas among small-cap funds, as well as take a look at two small caps that fit the "guru strategy" of Warren Buffett.

Newsletter Watch: JAKKS Pacific

One of Validea editor John Reese's latest picks is children's products retailer JAKKS Pacific (Nasdaq:JAKK), which passes the parameters based on the strategies of Kenneth Fisher, Peter Lynch and Benjamin Graham.

Newsletter Watch: Best bets among small cap funds and ETFs

This week, we examine Fidelity Investor editor Jim Lowell's outlook for the small-cap sector, favorite small-cap funds within the Fidelity family and his review of the top five small-cap ETFs.

Newsletter Watch: Xinyuan Real Estate

Having just spent several weeks touring China, Global Investing editor Vivian Lewis uncovered several intriguing new ideas, including one small-cap stock in the homebuilding sector — Xinyuan Real Estate (NYSE:XIN).

Newsletter Watch: Omrix Biopharmaceuticals

See why Bill Martin, editor of BullMarket.com and founder of RagingBull.com, recently turned his analysis to Omrix Biopharmaceuticals (Nasdaq:OMRI).